

Sinoatrial node cardiomyocytes derived from human pluripotent stem cells as a biological pacemaker

Nature Biotechnology

35, 56-68

DOI: [10.1038/nbt.3745](https://doi.org/10.1038/nbt.3745)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Induced Pluripotent Stem Cell-Based Treatment of Acquired Heart Block. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, e005331.	2.1	0
2	Programming cells for cardiac repair. <i>Current Opinion in Biotechnology</i> , 2017, 47, 43-50.	3.3	5
3	Concise Review: Criteria for Chamber-Specific Categorization of Human Cardiac Myocytes Derived from Pluripotent Stem Cells. <i>Stem Cells</i> , 2017, 35, 1881-1897.	1.4	51
4	Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 3711-3739.	2.4	51
5	Organ-on-a-chip devices advance to market. <i>Lab on A Chip</i> , 2017, 17, 2395-2420.	3.1	307
6	Induced Pluripotent Stem Cells 10 Years Later. <i>Circulation Research</i> , 2017, 120, 1958-1968.	2.0	218
7	Human pluripotent stem cell-derived epicardial progenitors can differentiate to endocardial-like endothelial cells. <i>Bioengineering and Translational Medicine</i> , 2017, 2, 191-201.	3.9	43
8	Biomarkers of Human Pluripotent Stem Cell-Derived Cardiac Lineages. <i>Trends in Molecular Medicine</i> , 2017, 23, 651-668.	3.5	21
9	Ablation of Atrial Ganglionated Plexi to Treat Symptomatic Sinus Bradycardia. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 960-961.	1.3	7
10	Stem Cells in Cardiovascular Medicine: the Road to Regenerative Therapies. <i>Current Cardiology Reports</i> , 2017, 19, 34.	1.3	8
11	Specific Cell (Re-)Programming: Approaches and Perspectives. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2017, 163, 71-115.	0.6	3
12	Scalable Cardiac Differentiation of Pluripotent Stem Cells Using Specific Growth Factors and Small Molecules. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2017, 163, 39-69.	0.6	20
13	Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 1039-1059.	1.2	83
14	(Re-)programming of subtype specific cardiomyocytes. <i>Advanced Drug Delivery Reviews</i> , 2017, 120, 142-167.	6.6	13
15	Human iPSC-Derived Cardiomyocytes for Investigation of Disease Mechanisms and Therapeutic Strategies in Inherited Arrhythmia Syndromes: Strengths and Limitations. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 325-344.	1.3	62
16	Human Pluripotent Stem Cell-Derived Atrial and Ventricular Cardiomyocytes Develop from Distinct Mesoderm Populations. <i>Cell Stem Cell</i> , 2017, 21, 179-194.e4.	5.2	329
17	Human Embryonic Stem Cell-Derived Cardiomyocytes Self-Arrange with Areas of Different Subtypes During Differentiation. <i>Stem Cells and Development</i> , 2017, 26, 1566-1577.	1.1	14
18	Bioengineered Cardiac Tissue Based on Human Stem Cells for Clinical Application. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2017, 163, 117-146.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Biophysical stimulation for <i>in vitro</i> engineering of functional cardiac tissues. <i>Clinical Science</i> , 2017, 131, 1393-1404.	1.8	18
20	Recent Progress Using Pluripotent Stem Cells for Cardiac Regenerative Therapy. <i>Circulation Journal</i> , 2017, 81, 929-935.	0.7	13
21	Cardiac Sodium Channel Disease Modeling Using Patient-Derived Induced Pluripotent Stem Cells. <i>Circulation Journal</i> , 2017, 81, 1764-1765.	0.7	0
22	3D Bioprinting and In Vitro Cardiovascular Tissue Modeling. <i>Bioengineering</i> , 2017, 4, 71.	1.6	57
23	Overexpression of Map3k7 activates sinoatrial node-like differentiation in mouse ES-derived cardiomyocytes. <i>PLoS ONE</i> , 2017, 12, e0189818.	1.1	10
24	Subtype-specific differentiation of cardiac pacemaker cell clusters from human induced pluripotent stem cells. <i>Stem Cell Research and Therapy</i> , 2017, 8, 229.	2.4	46
25	Current Strategies and Challenges for Purification of Cardiomyocytes Derived from Human Pluripotent Stem Cells. <i>Theranostics</i> , 2017, 7, 2067-2077.	4.6	46
26	Cardiac progenitor cells application in cardiovascular disease. <i>Journal of Cardiovascular and Thoracic Research</i> , 2017, 9, 127-132.	0.3	41
27	Engineering and Application of Pluripotent Stem Cells. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2018, , .	0.6	0
28	Cardiac recovery via extended cell-free delivery of extracellular vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells. <i>Nature Biomedical Engineering</i> , 2018, 2, 293-303.	11.6	249
29	Cardiac differentiation of pluripotent stem cells and implications for modeling the heart in health and disease. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	53
30	NKX2-5 regulates human cardiomyogenesis via a HEY2 dependent transcriptional network. <i>Nature Communications</i> , 2018, 9, 1373.	5.8	77
31	Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e000043.	1.6	159
32	Spaceflight Activates Protein Kinase C Alpha Signaling and Modifies the Developmental Stage of Human Neonatal Cardiovascular Progenitor Cells. <i>Stem Cells and Development</i> , 2018, 27, 805-818.	1.1	14
33	Applications of genetically engineered human pluripotent stem cell reporters in cardiac stem cell biology. <i>Current Opinion in Biotechnology</i> , 2018, 52, 66-73.	3.3	6
34	Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation. <i>Molecular Therapy</i> , 2018, 26, 1624-1634.	3.7	63
35	In vitro platform of allogeneic stem cell-derived cardiomyocyte transplantation for cardiac conduction defects. <i>Europace</i> , 2018, 20, 1553-1560.	0.7	2
36	Isolation and characterization of ventricular-like cells derived from NKX2-5 and MLC2v double knock-in human pluripotent stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 1278-1284.	1.0	9

#	ARTICLE	IF	CITATIONS
37	Next-generation pacemakers: from small devices to biological pacemakers. <i>Nature Reviews Cardiology</i> , 2018, 15, 139-150.	6.1	123
38	2. Preclinical large-animal models of cardiovascular regeneration. , 2018, , 20-33.		0
39	Big bottlenecks in cardiovascular tissue engineering. <i>Communications Biology</i> , 2018, 1, 199.	2.0	66
40	Geometry-Dependent Arrhythmias in Electrically Excitable Tissues. <i>Cell Systems</i> , 2018, 7, 359-370.e6.	2.9	30
42	Gene Therapy Approaches to Biological Pacemakers. <i>Journal of Cardiovascular Development and Disease</i> , 2018, 5, 50.	0.8	7
43	Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Korean Circulation Journal</i> , 2018, 48, 974.	0.7	21
44	Quantification of Cardiomyocyte Beating Frequency Using Fourier Transform Analysis. <i>Photonics</i> , 2018, 5, 39.	0.9	5
45	Shox2: The Role in Differentiation and Development of Cardiac Conduction System. <i>Tohoku Journal of Experimental Medicine</i> , 2018, 244, 177-186.	0.5	13
46	Dynamic Cellular Integration Drives Functional Assembly of the Heart's Pacemaker Complex. <i>Cell Reports</i> , 2018, 23, 2283-2291.	2.9	17
47	Spatially resolved RNA-sequencing of the embryonic heart identifies a role for Wnt/ β -catenin signaling in autonomic control of heart rate. <i>ELife</i> , 2018, 7, .	2.8	41
48	Recent Progress in Stem Cell Modification for Cardiac Regeneration. <i>Stem Cells International</i> , 2018, 2018, 1-22.	1.2	60
49	Embryonic Tbx3+ cardiomyocytes form the mature cardiac conduction system by progressive fate restriction. <i>Development (Cambridge)</i> , 2018, 145, .	1.2	27
50	Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as Models for Cardiac Channelopathies. <i>Circulation Research</i> , 2018, 123, 224-243.	2.0	74
51	Direct Reprogramming to Regenerate Myocardium and Repair Its Pacemaker and Conduction System. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 48.	0.7	3
52	Induction of Human Induced Pluripotent Stem Cells to Cardiomyocytes Using Embryoid Bodies. <i>Methods in Molecular Biology</i> , 2018, 1816, 79-92.	0.4	15
54	HCN4-Overexpressing Mouse Embryonic Stem Cell-Derived Cardiomyocytes Generate a New Rapid Rhythm in Rats with Bradycardia. <i>International Heart Journal</i> , 2018, 59, 601-606.	0.5	9
55	Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 2607-2655.	1.1	159
56	Transcriptional regulation of the cardiac conduction system. <i>Nature Reviews Cardiology</i> , 2018, 15, 617-630.	6.1	84

#	ARTICLE	IF	CITATIONS
57	Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models. <i>Advanced Drug Delivery Reviews</i> , 2019, 140, 3-11.	6.6	72
58	Cardiac Tissue. , 2019, , 1073-1099.		3
59	Canonical Wnt5b Signaling Directs Outlying Nkx2.5+ Mesoderm into Pacemaker Cardiomyocytes. <i>Developmental Cell</i> , 2019, 50, 729-743.e5.	3.1	58
60	Chromatin compartment dynamics in a haploinsufficient model of cardiac laminopathy. <i>Journal of Cell Biology</i> , 2019, 218, 2919-2944.	2.3	46
61	In Vitro Generation of Heart Field-specific Cardiac Progenitor Cells. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	7
62	Learn from Your Elders: Developmental Biology Lessons to Guide Maturation of Stem Cell-Derived Cardiomyocytes. <i>Pediatric Cardiology</i> , 2019, 40, 1367-1387.	0.6	47
63	Continuous WNT Control Enables Advanced hPSC Cardiac Processing and Prognostic Surface Marker Identification in Chemically Defined Suspension Culture. <i>Stem Cell Reports</i> , 2019, 13, 366-379.	2.3	61
64	Transcription Factor prrx1 Promotes Brown Adipose-Derived Stem Cells Differentiation to Sinus Node-Like Cells. <i>DNA and Cell Biology</i> , 2019, 38, 1313-1322.	0.9	7
65	hiPSCs Derived Cardiac Cells for Drug and Toxicity Screening and Disease Modeling: What Micro-Electrode-Array Analyses Can Tell Us. <i>Cells</i> , 2019, 8, 1331.	1.8	51
66	Cardiomyogenesis Modeling Using Pluripotent Stem Cells: The Role of Microenvironmental Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 164.	1.8	24
67	Human Pluripotent Stem Cell-Derived Cardiovascular Cells: From Developmental Biology to Therapeutic Applications. <i>Cell Stem Cell</i> , 2019, 25, 311-327.	5.2	106
68	Canonical Wnt Signaling Sets the Pace. <i>Developmental Cell</i> , 2019, 50, 675-676.	3.1	4
69	Functional biological pacemaker generation by T-Box18 protein expression via stem cell and viral delivery approaches in a murine model of complete heart block. <i>Pharmacological Research</i> , 2019, 141, 443-450.	3.1	19
70	ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure. <i>Cardiovascular Research</i> , 2019, 115, 488-500.	1.8	90
71	Genetic variation in <i>GNB5</i> causes bradycardia by increasing IK _{ACh} augmenting cholinergic response. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	19
72	Pluripotent Stem Cell-Derived Cardiomyocyte Transplantation for Heart Disease Treatment. <i>Current Cardiology Reports</i> , 2019, 21, 73.	1.3	26
73	A comprehensive, multiscale framework for evaluation of arrhythmias arising from cell therapy in the whole post-myocardial infarcted heart. <i>Scientific Reports</i> , 2019, 9, 9238.	1.6	21
74	A rat model of complete atrioventricular block recapitulates clinical indices of bradycardia and provides a platform to test disease-modifying therapies. <i>Scientific Reports</i> , 2019, 9, 6930.	1.6	13

#	ARTICLE	IF	CITATIONS
75	Concise Review: Genetic and Epigenetic Regulation of Cardiac Differentiation from Human Pluripotent Stem Cells. <i>Stem Cells</i> , 2019, 37, 992-1002.	1.4	32
76	Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate the Infarcted Pig Heart but Induce Ventricular Tachyarrhythmias. <i>Stem Cell Reports</i> , 2019, 12, 967-981.	2.3	207
77	Non-contact monitoring of extra-cellular field potentials with a multi-electrode array. <i>Lab on A Chip</i> , 2019, 19, 1448-1457.	3.1	6
78	Cardiac macrotissues-on-a-plate models for phenotypic drug screens. <i>Advanced Drug Delivery Reviews</i> , 2019, 140, 93-100.	6.6	21
79	Addressing Variability and Heterogeneity of Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1212, 1-29.	0.8	19
80	A Human iPSC Double-Reporter System Enables Purification of Cardiac Lineage Subpopulations with Distinct Function and Drug Response Profiles. <i>Cell Stem Cell</i> , 2019, 24, 802-811.e5.	5.2	102
81	Bioengineering adult human heart tissue: How close are we?. <i>APL Bioengineering</i> , 2019, 3, 010901.	3.3	43
82	Dissecting hiPSC-CM pacemaker function in a cardiac organoid model. <i>Biomaterials</i> , 2019, 206, 133-145.	5.7	21
83	Transcriptome analysis of mouse and human sinoatrial node cells reveals a conserved genetic program. <i>Development (Cambridge)</i> , 2019, 146, .	1.2	54
84	Modeling cardiac complexity: Advancements in myocardial models and analytical techniques for physiological investigation and therapeutic development <i>in vitro</i> . <i>APL Bioengineering</i> , 2019, 3, 011501.	3.3	11
85	Comparison of Cultured Human Cardiomyocyte Clusters Obtained from Embryos/Fetuses or Derived from Human Embryonic Stem Cells. <i>Stem Cells and Development</i> , 2019, 28, 608-619.	1.1	2
86	Modelling of Genetic Cardiac Diseases. , 0, , .		1
87	Transcriptomically Guided Mesendoderm Induction of Human Pluripotent Stem Cells Using a Systematically Defined Culture Scheme. <i>Stem Cell Reports</i> , 2019, 13, 1111-1125.	2.3	4
88	Pacemaking in cardiac tissue. From IK2 to a coupled-clock system. <i>Physiological Reports</i> , 2019, 7, e13862.	0.7	22
89	Systems-Wide Approaches in Induced Pluripotent Stem Cell Models. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 395-419.	9.6	24
90	The Cardiac Pacemaker. , 2019, , 153-178.		1
91	Cardiovascular disease models: A game changing paradigm in drug discovery and screening. <i>Biomaterials</i> , 2019, 198, 3-26.	5.7	149
92	Canonical Wnt signaling promotes pacemaker cell specification of cardiac mesodermal cells derived from mouse and human embryonic stem cells. <i>Stem Cells</i> , 2020, 38, 352-368.	1.4	55

#	ARTICLE	IF	CITATIONS
93	Heart regeneration: from mouse to human. <i>Current Opinion in Physiology</i> , 2020, 14, 7-12.	0.9	3
94	Human induced pluripotent stem cell line with genetically encoded fluorescent voltage indicator generated via CRISPR for action potential assessment post-cardiogenesis. <i>Stem Cells</i> , 2020, 38, 90-101.	1.4	20
95	The roles and regulation of TBX3 in development and disease. <i>Gene</i> , 2020, 726, 144223.	1.0	51
96	<i>HCN2</i> and <i>TBX3</i> Reprogram Human-Induced Pluripotent Stem Cells-Derived Cardiomyocytes into Pacemaker-Like Cells. <i>DNA and Cell Biology</i> , 2020, 39, 289-298.	0.9	7
97	Towards chamber specific heart-on-a-chip for drug testing applications. <i>Advanced Drug Delivery Reviews</i> , 2020, 165-166, 60-76.	6.6	52
98	Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes. <i>Nature Communications</i> , 2020, 11, 75.	5.8	148
99	Inductive factors for generation of pluripotent stem cell-derived cardiomyocytes. , 2020, , 177-242.		1
100	Cardiopharyngeal Progenitor Specification: Multiple Roads to the Heart and Head Muscles. <i>Cold Spring Harbor Perspectives in Biology</i> , 2020, 12, a036731.	2.3	16
101	Gene and Cell Therapy for Cardiac Arrhythmias. <i>Clinical Therapeutics</i> , 2020, 42, 1911-1922.	1.1	8
102	The Quantitative Relationship among the Number of the Pacing Cells Required, the Dimension, and the Diffusion Coefficient. <i>BioMed Research International</i> , 2020, 2020, 1-11.	0.9	0
103	Robust Cardiac Regeneration: Fulfilling the Promise of Cardiac Cell Therapy. <i>Clinical Therapeutics</i> , 2020, 42, 1857-1879.	1.1	7
104	Genome-Wide Analysis Identifies an Essential Human TBX3 Pacemaker Enhancer. <i>Circulation Research</i> , 2020, 127, 1522-1535.	2.0	22
105	Stem Cells and Their Cardiac Derivatives for Cardiac Tissue Engineering and Regenerative Medicine. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 143-162.	2.5	12
106	Heart regeneration using pluripotent stem cells. <i>Journal of Cardiology</i> , 2020, 76, 459-463.	0.8	17
107	Rapamycin Promotes Cardiomyocyte Differentiation of Human Induced Pluripotent Stem Cells in a Stage-Dependent Manner. <i>Stem Cells and Development</i> , 2020, 29, 1229-1239.	1.1	5
108	Enrichment differentiation of human induced pluripotent stem cells into sinoatrial node-like cells by combined modulation of BMP, FGF, and RA signaling pathways. <i>Stem Cell Research and Therapy</i> , 2020, 11, 284.	2.4	20
109	Increased predominance of the matured ventricular subtype in embryonic stem cell-derived cardiomyocytes in vivo. <i>Scientific Reports</i> , 2020, 10, 11883.	1.6	26
110	Enhancing Matured Stem-Cardiac Cell Generation and Transplantation: A Novel Strategy for Heart Failure Therapy. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 556-572.	1.1	8

#	ARTICLE	IF	CITATIONS
111	Single-Cell Mechanical Analysis of Human Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Testing and Pathophysiological Studies. <i>Stem Cell Reports</i> , 2020, 15, 587-596.	2.3	13
112	Overexpression of TBX3 in human induced pluripotent stem cells (hiPSCs) increases their differentiation into cardiac pacemaker-like cells. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110612.	2.5	17
113	NODAL inhibition promotes differentiation of pacemaker-like cardiomyocytes from human induced pluripotent stem cells. <i>Stem Cell Research</i> , 2020, 49, 102043.	0.3	19
114	Assessment of Cardiotoxicity With Stem Cell-based Strategies. <i>Clinical Therapeutics</i> , 2020, 42, 1892-1910.	1.1	11
115	Cells, Materials, and Fabrication Processes for Cardiac Tissue Engineering. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 955.	2.0	32
116	From Human Pluripotent Stem Cells to 3D Cardiac Microtissues: Progress, Applications and Challenges. <i>Bioengineering</i> , 2020, 7, 92.	1.6	8
117	hiPSC-Derived Cardiac Tissue for Disease Modeling and Drug Discovery. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8893.	1.8	27
118	Metabolic environment in vivo as a blueprint for differentiation and maturation of human stem cell-derived cardiomyocytes. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165881.	1.8	14
119	Impact of Chronic Fetal Hypoxia and Inflammation on Cardiac Pacemaker Cell Development. <i>Cells</i> , 2020, 9, 733.	1.8	12
120	Subtype-specific cardiomyocytes for precision medicine: Where are we now?. <i>Stem Cells</i> , 2020, 38, 822-833.	1.4	24
121	A Brief History of Pacemaking. <i>Frontiers in Physiology</i> , 2020, 10, 1599.	1.3	28
122	Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. <i>Pharmacological Reviews</i> , 2020, 72, 320-342.	7.1	121
123	Development of a sheep model of atrioventricular block for the application of novel therapies. <i>PLoS ONE</i> , 2020, 15, e0229092.	1.1	4
124	Toward the realization of cardiac regenerative medicine using pluripotent stem cells. <i>Inflammation and Regeneration</i> , 2020, 40, 1.	1.5	62
125	The Emergence of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) as a Platform to Model Arrhythmogenic Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 657.	1.8	28
126	Arrhythmogenic risks of stem cell replacement therapy for cardiovascular diseases. <i>Journal of Cellular Physiology</i> , 2020, 235, 6257-6267.	2.0	12
127	Cellular Reprogramming Approaches to Engineer Cardiac Pacemakers. <i>Current Cardiology Reports</i> , 2020, 22, 29.	1.3	2
128	Cardiac progenitor cells, tissue homeostasis, and regeneration. , 2020, , 579-591.		0

#	ARTICLE	IF	CITATIONS
129	Cardiac tissue engineering. , 2020, , 593-616.		2
130	Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 50.	1.1	36
131	Development of the Cardiac Conduction System. <i>Cold Spring Harbor Perspectives in Biology</i> , 2020, 12, a037408.	2.3	20
132	Human-induced pluripotent stem cells as models for rare cardiovascular diseases: from evidence-based medicine to precision medicine. <i>Pflugers Archiv European Journal of Physiology</i> , 2021, 473, 1151-1165.	1.3	13
133	A Concise Review on Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Personalized Regenerative Medicine. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 748-776.	1.7	13
134	Toward Biological Pacing by Cellular Delivery of Hcn2/SkM1. <i>Frontiers in Physiology</i> , 2020, 11, 588679.	1.3	5
135	Tissue Chips and Microphysiological Systems for Disease Modeling and Drug Testing. <i>Micromachines</i> , 2021, 12, 139.	1.4	11
136	Drug Discovery in Induced Pluripotent Stem Cell Models. , 2021, , .		0
137	Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research. <i>Pflugers Archiv European Journal of Physiology</i> , 2021, 473, 1061-1085.	1.3	42
138	Sinoatrial node pacemaker cells: cardiomyocyte- or neuron-like cells?. <i>Protein and Cell</i> , 2021, 12, 518-519.	4.8	3
139	iPSC-Cardiomyocyte Models of Brugada Syndrome—Achievements, Challenges and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2825.	1.8	13
140	Genetic Cardiomyopathies: The Lesson Learned from hiPSCs. <i>Journal of Clinical Medicine</i> , 2021, 10, 1149.	1.0	8
141	Human-induced pluripotent stem cells in cardiovascular research: current approaches in cardiac differentiation, maturation strategies, and scalable production. <i>Cardiovascular Research</i> , 2022, 118, 20-36.	1.8	27
142	Isolation and characterization of human embryonic stem cell-derived heart field-specific cardiomyocytes unravels new insights into their transcriptional and electrophysiological profiles. <i>Cardiovascular Research</i> , 2022, 118, 828-843.	1.8	14
143	Bioengineering Clinically Relevant Cardiomyocytes and Cardiac Tissues from Pluripotent Stem Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3005.	1.8	11
144	Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 50-63.	2.8	15
145	Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 655161.	1.8	9
146	Drawing Inspiration from Developmental Biology for Cardiac Tissue Engineers. <i>Advanced Biology</i> , 2021, 5, 2000190.	1.4	4

#	ARTICLE	IF	CITATIONS
147	A dual cardiomyocyte reporter model derived from human pluripotent stem cells. <i>Stem Cell Research and Therapy</i> , 2021, 12, 305.	2.4	0
148	Myosin light chain 2 marks differentiating ventricular cardiomyocytes derived from human embryonic stem cells. <i>Pflugers Archiv European Journal of Physiology</i> , 2021, 473, 991-1007.	1.3	14
149	A detailed characterization of the hyperpolarization-activated I_{f} in human-induced pluripotent stem cell (iPSC)-derived cardiomyocytes with pacemaker activity. <i>Pflugers Archiv European Journal of Physiology</i> , 2021, 473, 1009-1021.	1.3	18
150	Model Systems for Addressing Mechanism of Arrhythmogenesis in Cardiac Repair. <i>Current Cardiology Reports</i> , 2021, 23, 72.	1.3	1
151	Designing of spider silk proteins for human induced pluripotent stem cell-based cardiac tissue engineering. <i>Materials Today Bio</i> , 2021, 11, 100114.	2.6	19
152	Harnessing organs-on-a-chip to model tissue regeneration. <i>Cell Stem Cell</i> , 2021, 28, 993-1015.	5.2	36
153	Downregulated lncRNA RCPCD promotes differentiation of embryonic stem cells into cardiac pacemaker-like cells by suppressing HCN4 promoter methylation. <i>Cell Death and Disease</i> , 2021, 12, 667.	2.7	8
154	Molecular Profiling of the Cardiac Conduction System: the Dawn of a New Era. <i>Current Cardiology Reports</i> , 2021, 23, 103.	1.3	3
157	Epigenetic Regulation of Cardiomyocyte Differentiation from Embryonic and Induced Pluripotent Stem Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8599.	1.8	5
158	<i>In vitro</i> models of the human heart. <i>Development (Cambridge)</i> , 2021, 148, .	1.2	15
159	Bioengineering approaches to treat the failing heart: from cell biology to 3D printing. <i>Nature Reviews Cardiology</i> , 2022, 19, 83-99.	6.1	36
160	Bioengineering the Cardiac Conduction System: Advances in Cellular, Gene, and Tissue Engineering for Heart Rhythm Regeneration. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 673477.	2.0	9
161	Zebrafish Models in Therapeutic Research of Cardiac Conduction Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 731402.	1.8	2
163	Human iPS-derived pre-epicardial cells direct cardiomyocyte aggregation expansion and organization in vitro. <i>Nature Communications</i> , 2021, 12, 4997.	5.8	21
164	E2A ablation enhances proportion of nodal-like cardiomyocytes in cardiac-specific differentiation of human embryonic stem cells. <i>EBioMedicine</i> , 2021, 71, 103575.	2.7	4
165	Approaches to Optimize Stem Cell-Derived Cardiomyocyte Maturation and Function. <i>Current Stem Cell Reports</i> , 0, , 1.	0.7	0
166	Implementing Biological Pacemakers: Design Criteria for Successful Transition From Concept to Clinic. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009957.	2.1	10
167	Of form and function: Early cardiac morphogenesis across classical and emerging model systems. <i>Seminars in Cell and Developmental Biology</i> , 2021, 118, 107-118.	2.3	5

#	ARTICLE	IF	CITATIONS
169	Role of ion channels in human induced pluripotent stem cellsâ€‘derived cardiomyocytes. , 2022, , 219-248.		0
170	Computational modeling of aberrant electrical activity following remuscularization with intramyocardially injected pluripotent stem cell-derived cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2022, 162, 97-109.	0.9	12
171	Cellular and molecular landscape of mammalian sinoatrial node revealed by single-cell RNA sequencing. Nature Communications, 2021, 12, 287.	5.8	55
172	Decoding Genetics of Congenital Heart Disease Using Patient-Derived Induced Pluripotent Stem Cells (iPSCs). Frontiers in Cell and Developmental Biology, 2021, 9, 630069.	1.8	17
173	Stem Cell Therapy of Myocardial Infarction: A Promising Opportunity in Bioengineering. Advanced Therapeutics, 2020, 3, 1900182.	1.6	15
174	Pluripotent Stem Cells for Cardiac Regenerationâ€‘ Current Status, Challenges, and Future Perspectives â€‘. Circulation Journal, 2020, 84, 2129-2135.	0.7	5
175	The prospects of creating a pacemaker cardiac tissue using modern technologies. Genes and Cells, 2017, 12, 29-36.	0.2	4
176	Multiplex live single-cell transcriptional analysis demarcates cellular functional heterogeneity. ELife, 2019, 8, .	2.8	5
177	Trait-associated noncoding variant regions affect TBX3 regulation and cardiac conduction. ELife, 2020, 9, .	2.8	7
178	Retinoic acid signaling in heart development: Application in the differentiation of cardiovascular lineages from human pluripotent stem cells. Stem Cell Reports, 2021, 16, 2589-2606.	2.3	28
179	A framework for developing sex-specific engineered heart models. Nature Reviews Materials, 2022, 7, 295-313.	23.3	22
180	Recent progress of iPSC technology in cardiac diseases. Archives of Toxicology, 2021, 95, 3633-3650.	1.9	18
184	Model of optical biopacemaker based on integration of photosensitive cardiomyocytes into cardiac culture. Genes and Cells, 2018, 13, 43-50.	0.2	0
185	Survival and functional activity examination of cardiomyocytes differentiated from human iPSCs, when transplanting in SCID mice. Genes and Cells, 2018, 13, 51-60.	0.2	1
186	Biomaterial Control of Differentiation of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells. Biomaterials Science Series, 2019, , 252-327.	0.1	0
188	Unravelling Atrioventricular Block Risk in Inflammatory Diseases: Systemic Inflammation Acutely Delays Atrioventricular Conduction via a Cytokineâ€‘Mediated Inhibition of Connexin43 Expression. Journal of the American Heart Association, 2021, 10, e022095.	1.6	10
189	Cell therapy approaches for treatment of bradyarrhythmias. , 2020, , 841-859.		0
190	Molecular therapies forÂbradyarrhythmias. , 2020, , 811-840.		0

#	ARTICLE	IF	CITATIONS
191	Biomaterial-induced conversion of quiescent cardiomyocytes into pacemaker cells in rats. <i>Nature Biomedical Engineering</i> , 2022, 6, 421-434.	11.6	17
192	Microelectrode Arrays: A Valuable Tool to Analyze Stem Cell-Derived Cardiomyocytes. , 2021, , 1-20.		1
193	Biosensor-based profiling to track cellular signalling in patient-derived models of dilated cardiomyopathy. <i>Cellular Signalling</i> , 2022, 91, 110239.	1.7	2
194	Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platformâ€”A Cardiac Perspective. <i>Cells</i> , 2021, 10, 3483.	1.8	7
195	<i>In vivo</i> and <i>in vitro</i> evaluation of chitosan-modified bioactive glass paste for wound healing. <i>Journal of Materials Chemistry B</i> , 2022, 10, 598-606.	2.9	4
196	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2022, 24, 406-420.	2.9	22
197	Revealing nervous and cardiac system interactions by iPSC-Based platforms. , 2022, , 1-28.		0
198	Induced pluripotent stem cells for modeling cardiac sodium channelopathies. , 2022, , 179-191.		0
200	Optogenetic Control of Human Induced Pluripotent Stem Cellâ€”Derived Cardiac Tissue Models. <i>Journal of the American Heart Association</i> , 2022, , e021615.	1.6	4
203	The Biphasic Effect of Retinoic Acid Signaling Pathway on the Biased Differentiation of Atrial-like and Sinoatrial Node-like Cells from hiPSC. <i>International Journal of Stem Cells</i> , 2022, 15, 247-257.	0.8	2
204	Deconvoluting the Cells of the Human Heart with iPSC Technology: Cell Types, Protocols, and Uses. <i>Current Cardiology Reports</i> , 2022, 24, 487-496.	1.3	4
205	Cardiac Cell Therapy with Pluripotent Stem Cell-Derived Cardiomyocytes: What Has Been Done and What Remains to Do?. <i>Current Cardiology Reports</i> , 2022, 24, 445-461.	1.3	10
206	Advances in Manufacturing Cardiomyocytes from Human Pluripotent Stem Cells. <i>Annual Review of Chemical and Biomolecular Engineering</i> , 2022, 13, 255-278.	3.3	3
207	SARS-CoV-2 Infection Induces Ferroptosis of Sinoatrial Node Pacemaker Cells. <i>Circulation Research</i> , 2022, 130, 963-977.	2.0	49
208	Enhancement of pacing function by HCN4 overexpression in human pluripotent stem cell-derived cardiomyocytes. <i>Stem Cell Research and Therapy</i> , 2022, 13, 141.	2.4	3
209	A dual SHOX2:GFP; MYH6:mCherry knockin hESC reporter line for derivation of human SAN-like cells. <i>IScience</i> , 2022, 25, 104153.	1.9	1
210	Cpmer: A new conserved eEF1A2-binding partner that regulates Eomes translation and cardiomyocyte differentiation. <i>Stem Cell Reports</i> , 2022, 17, 1154-1169.	2.3	11
211	Tbx18 promoted the conversion of humanâ€”induced pluripotent stem cellâ€”derived cardiomyocytes into sinoatrial nodeâ€”like pacemaker cells. <i>Cell Biology International</i> , 2022, 46, 403-414.	1.4	7

#	ARTICLE	IF	CITATIONS
212	Next-generation pacemakers: from electrical devices to biological pacemakers. <i>Kazan Medical Journal</i> , 2021, 102, 916-922.	0.1	0
214	The Molecular and Cellular Mechanisms of Heart Pacemaker Development in Vertebrates. <i>Moscow University Biological Sciences Bulletin</i> , 2021, 76, 147-164.	0.1	4
215	Chemically defined and small molecules-based generation of sinoatrial node-like cells. <i>Stem Cell Research and Therapy</i> , 2022, 13, 158.	2.4	8
216	Modeling Human Heart Development and Congenital Defects Using Organoids: How Close Are We?. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 125.	0.8	3
217	Opportunities and challenges in cardiac tissue engineering from an analysis of two decades of advances. <i>Nature Biomedical Engineering</i> , 2022, 6, 327-338.	11.6	25
218	Increase in Ca ²⁺ -Activated cAMP/PKA Signaling Prevents Hydroxychloroquine-Induced Bradycardia of the Cardiac Pacemaker. <i>Frontiers in Physiology</i> , 2022, 13, .	1.3	4
219	Scalable manufacturing of clinical-grade differentiated cardiomyocytes derived from human-induced pluripotent stem cells for regenerative therapy. <i>Cell Proliferation</i> , 2022, 55, e13248.	2.4	6
221	Cellular and Engineered Organoids for Cardiovascular Models. <i>Circulation Research</i> , 2022, 130, 1780-1802.	2.0	27
222	Purification of human iPSC-derived cells at large scale using microRNA switch and magnetic-activated cell sorting. <i>Stem Cell Reports</i> , 2022, 17, 1772-1785.	2.3	9
223	Improved Generation of Human Induced Pluripotent Stem Cell-Derived Cardiac Pacemaker Cells Using Novel Differentiation Protocols. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7318.	1.8	4
224	RA signaling pathway combined with Wnt signaling pathway regulates human-induced pluripotent stem cells (hiPSCs) differentiation to sinus node-like cells. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	5
225	Recombinant Adeno-Associated Viral Vector-Mediated Gene Transfer of hTBX18 Generates Pacemaker Cells from Ventricular Cardiomyocytes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9230.	1.8	2
226	Fabrication of human myocardium using multidimensional modelling of engineered tissues. <i>Biofabrication</i> , 2022, 14, 045017.	3.7	2
227	Challenges and innovation: Disease modeling using human-induced pluripotent stem cell-derived cardiomyocytes. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
228	The Advantages, Challenges, and Future of Human-Induced Pluripotent Stem Cell Lines in Type 2 Long QT Syndrome. <i>Journal of Cardiovascular Translational Research</i> , 0, , .	1.1	0
229	A review of protocols for human iPSC culture, cardiac differentiation, subtype-specification, maturation, and direct reprogramming. <i>STAR Protocols</i> , 2022, 3, 101560.	0.5	36
230	SHOX2 refines the identification of human sinoatrial nodal cell population in the in vitro cardiac differentiation. <i>Regenerative Therapy</i> , 2022, 21, 239-249.	1.4	2
231	devCellPy is a machine learning-enabled pipeline for automated annotation of complex multilayered single-cell transcriptomic data. <i>Nature Communications</i> , 2022, 13, .	5.8	16

#	ARTICLE	IF	CITATIONS
253	Biophysical Stretch Induced Differentiation and Maturation of Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Cardiac and Vascular Biology</i> , 2023, , 141-179.	0.2	0
254	Genes, environments, and epigenetics. , 2023, , 181-200.		0
260	Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy. <i>Handbook of Experimental Pharmacology</i> , 2023, , .	0.9	0
264	Mikroelektroden-Arrays: Ein wertvolles Instrument zur Analyse von aus Stammzellen gewonnenen Kardiomyozyten. , 2023, , 1-24.		0
266	Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity. <i>Cell Biology and Toxicology</i> , 2023, 39, 2527-2549.	2.4	1
270	The "Funny" Pacemaker Current. , 2023, , 63-87.		0